The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares an overview of the phase III RELEVANCE trial (NCT01650701) of rituximab and lenalidomide (R2) versus rituximab-chemotherapy followed by rituximab maintenance in patients with high tumor burden, untreated follicular lymphoma (FL). Six years after initial treatment, both treatment arms demonstrated similar efficacy and survival, highlighting R2 as a viable chemotherapy-free treatment option. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
